Neural-net-based cell deconvolution from DNA methylation reveals tumor microenvironment associated with cancer prognosis.


Journal

NAR cancer
ISSN: 2632-8674
Titre abrégé: NAR Cancer
Pays: England
ID NLM: 101769553

Informations de publication

Date de publication:
Jun 2024
Historique:
received: 06 02 2024
revised: 18 04 2024
accepted: 01 05 2024
medline: 16 5 2024
pubmed: 16 5 2024
entrez: 16 5 2024
Statut: epublish

Résumé

DNA methylation is a pivotal epigenetic modification that defines cellular identity. While cell deconvolution utilizing this information is considered useful for clinical practice, current methods for deconvolution are limited in their accuracy and resolution. In this study, we collected DNA methylation data from 945 human samples derived from various tissues and tumor-infiltrating immune cells and trained a neural network model with them. The model, termed MEnet, predicted abundance of cell population together with the detailed immune cell status from bulk DNA methylation data, and showed consistency to those of flow cytometry and histochemistry. MEnet was superior to the existing methods in the accuracy, speed, and detectable cell diversity, and could be applicable for peripheral blood, tumors, cell-free DNA, and formalin-fixed paraffin-embedded sections. Furthermore, by applying MEnet to 72 intrahepatic cholangiocarcinoma samples, we identified immune cell profiles associated with cancer prognosis. We believe that cell deconvolution by MEnet has the potential for use in clinical settings.

Identifiants

pubmed: 38751935
doi: 10.1093/narcan/zcae022
pii: zcae022
pmc: PMC11094754
doi:

Types de publication

Journal Article

Langues

eng

Pagination

zcae022

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of NAR Cancer.

Auteurs

Yoshiaki Yasumizu (Y)

Department of Experimental Immunology, Immunology Frontier Research Center, Osaka University, Suita, Osaka, Japan.
Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives (OTRI), Osaka University, Suita, Osaka, Japan.

Masaki Hagiwara (M)

Department of Experimental Immunology, Immunology Frontier Research Center, Osaka University, Suita, Osaka, Japan.
Department of Basic Research in Tumor Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Pharmaceutical Research Division, Shionogi & Co., Ltd., Toyonaka, Osaka, Japan.

Yuto Umezu (Y)

Faculty of Medicine, Osaka University, Suita, Osaka, Japan.

Hiroaki Fuji (H)

Department of Hepato-Biliary-Pancreatic Surgery, Hyogo Medical University, Nishinomiya, Hyogo, Japan.
Division of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan.

Keiko Iwaisako (K)

Division of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan.
Faculty of Life and Medical Sciences, Doshisha University, Kyotanabe, Kyoto, Japan.

Masataka Asagiri (M)

Department of Pharmacology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan.

Shinji Uemoto (S)

Shiga University Medical Science, Otsu, Shiga, Japan.

Yamami Nakamura (Y)

Department of Experimental Immunology, Immunology Frontier Research Center, Osaka University, Suita, Osaka, Japan.

Sophia Thul (S)

Department of Experimental Immunology, Immunology Frontier Research Center, Osaka University, Suita, Osaka, Japan.

Azumi Ueyama (A)

Pharmaceutical Research Division, Shionogi & Co., Ltd., Toyonaka, Osaka, Japan.
Department of Clinical Research in Tumor Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

Kazunori Yokoi (K)

Department of Dermatology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

Atsushi Tanemura (A)

Department of Dermatology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

Yohei Nose (Y)

Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

Takuro Saito (T)

Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

Hisashi Wada (H)

Department of Clinical Research in Tumor Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

Mamoru Kakuda (M)

Department of Obstetrics and Gynecology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

Masaharu Kohara (M)

Department of Pathology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

Satoshi Nojima (S)

Department of Pathology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

Eiichi Morii (E)

Department of Pathology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

Yuichiro Doki (Y)

Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

Shimon Sakaguchi (S)

Department of Experimental Immunology, Immunology Frontier Research Center, Osaka University, Suita, Osaka, Japan.
Department of Experimental Immunology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Kyoto, Japan.

Naganari Ohkura (N)

Department of Experimental Immunology, Immunology Frontier Research Center, Osaka University, Suita, Osaka, Japan.
Department of Basic Research in Tumor Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

Classifications MeSH